Adalimumab/Humira

  • Adalimumab is a monoclonal antibody, marketed under the brand name Humira. Adalimumab is marketed by the pharmaceutical company AbbVie.
  • It is a Phage display-derived therapeutic antibodies, humanized by Phage display guided selection using a naïve scFv-phage library using Cambridge Antibody Technology (CAT)
  • Antibody format: IgG1-κ 
  • It functions by blocking a tumor necrosis factor-alpha (TNF-α), a cytokine involved in systemic inflammation. 
  • It is available under the brand name Humira, as well as biosimilars (which are like generic versions of brand-name drugs). It is administered via subcutaneous injection (under the skin).
  • It an be used to treat several inflammatory/autoimmune conditions
    • Rheumatoid arthritis (Approved 2002)
    • Psoriatic arthritis (Approved 2005)
    • Ankylosing spondylitis (Approved 2006)
    • Crohn’s disease (Approved 2007)
    • Psoriasis, severe chronic plaque (Approved 2008)
    • Juvenile Idiopathic Arthritis (Approved 2008)
    • Ulcerative colitis (Approved 2012)
    • Hidradenitis suppurativa (Approved 2015)
    • Fingernail psoriasis (Approved 2017)
  • Common side effects may include injection site reactions, increased risk of infections, headaches and nausea.
  • Abbreviations:
    • TNF-α (tumor necrosis factor-alpha)

Note: The information presented here is for informational purposes only and should not be considered a substitute for professional medical advice. Always consult a healthcare provider for personalized guidance and recommendations.
Disclaimer: While we strive to provide accurate and up-to-date information, we cannot guarantee 100% accuracy. Please consult additional sources for verification.

Was this post helpful?

Author: admin

Leave a Reply

Your email address will not be published. Required fields are marked *